Rate of cognitive decline in preclinical Alzheimer's disease:: The role of comorbidity
Rate of cognitive decline in preclinical Alzheimer's disease:: The role of comorbidity
复制标题
DOI：
10.1093/geronb/58.4.p228
复制
发表时间：
2003-07-01
影响因子：
6.2
通讯作者：
Fratiglioni, L
中科院分区：
文献类型：
--
作者：
Bäckman, L;Jones, S;Fratiglioni, L
我们调查了个体差异变量对阿尔茨海默病（AD）风险因素或已知与正常衰老中认知表现相关的变量（例如，年龄、性别、受教育年限、既往和近期疾病、载脂蛋白E状态、社会网络和物质使用）对临床前到临床AD认知变化率的影响。使用一项基于人群的研究数据，230名基线时无痴呆且在3年随访中被诊断为AD的人接受了迷你精神状态检查（MMSE）的检查。在检查的所有预测变量中，只有在随访期间导致住院的疾病数量对MMSE变化率有独立贡献。这些结果表明，影响正常衰老过程中退行性过程和认知功能的许多变量对临床前AD认知变化率的影响很小。这可能反映了一个事实，即新出现的痴呆症掩盖了这些变量对认知功能的作用。这种模式的一个可能的例外是，在阿尔茨海默病临床前阶段的最后阶段，越来越多的伴随健康状况可能会加剧认知能力下降的速度。
We investigated the influence of individual-difference variables implicated as risk factors for Alzheimer's disease (AD) or known to be related to cognitive performance in normal aging (e.g., age, sex, years of education, previous and recent diseases, apolipoprotein E status, social network, and substance use) on rate of cognitive change from preclinical to clinical AD. With the use of data from a population-based study, 230 persons who were nondemented at baseline and diagnosed with AD at a 3-year follow-up were examined with the Mini-Mental State Examination (MMSE). Of all predictor variables examined, only number of diseases resulting in hospital admission during the follow-up period made an independent contribution to rate of MMSE change. These results suggest that many variables affecting the onset of the degenerative process as well as cognitive functioning in normal aging exert little influence on rate of cognitive change in preclinical AD. This may reflect the fact that the emerging dementia disease overshadows the role of these variables for cognitive functioning. A possible exception to this pattern is that an increasing number of concomitant health conditions may exacerbate the rate of cognitive decline during the final portion of the preclinical phase in AD.